Back to announcement
20241015_KLBF_Laporan Informasi dan Fakta Material_31746430_lamp2.pdf
Other Text extracted KLBFSource file signed link, expires in 15 minutes
Extracted text 2
Page 1 OCR 0.892
@ kate No. Letter 6 069/CSEC-KF/X-2024 Jakarta, October 15, 2024 Attachment : - Stock code: KLBF Re 5 Disclosure of Information To: Indonesia Financial Services Authority Gedung Soemitro Djojohadikusumo Jl. Lapangan Banteng Timur No. 2-4 Jakarta 10710 U.p.: Kepala Eksekutif Pengawas Pasar Modal Dear Sir / Madam, For and on behalf of the Company, hereby we disclose the following information or material facts: Name of Issuer or Public Company : PT Kalbe Farma Tbk (the “Company”) Business fields : Processing industry, activities professional, scientific, technical and supporting business Telephone : 021 - 42873888 Facsimile : 021 - 42873680 Email : maria.fabiola@kalbecorp.com corporate.secretary@kalbecorp.com 1. | Date of Event October 15, 2024 2. | Types of Material Information or | Submission — of information — regarding Facts Inauguration Domestic Radioisotope Production Facility. This transaction is neither a Material Transaction nor a Conflict of Interest Transaction based on the Financial Services Authority (Otoritas — Jasa Keuangan) Regulation. 3. | Description of Material |In compliance with Indonesia Financial | Information or Facts Services Authority Regulation No. | 31/POJK.04/2015 dated December 16, 2015, regarding Disclosure of Information or Material Facts by the Issuer or a Listed Company, the Company hereby announces that the Company through its subsidiary, PT Global Onkolab Farma (GOF), inaugurated radioisotope production facility — that produces Fluorodeoxyglucose (FDG) for the PT. KALBE FARMA Tbk. Head Office : Gedung KALBE, Jl. Let. Jend. Suprapto Kav. 4, Jakarta 10510, P.O. Box 9105 JAK, Jakarta, Indonesia. Tel. (021) 42873888 -89 Fax. (021) 42873680 Factory : Kawasan Industri Delta Silicon, Jl. M. H. Thamrin Blok A3 - 1, Lippo Cikarang, Bekasi 17550, P.O. Box 371 Bekasi 17037, Indonesia. Tel. (021)89907333 Fax. (021)8972874 info@kabe.coid
Page 2 OCR 0.894
( KALBE early detection of cancer. 4. |The impact of the incident, | The Radioisotope Factory that produces information, or material fact on the | Fluorodeoxyglucose (FDG) is expected to operational, law, financial | support the services for Positron Emission condition, or business continuity of | Tomography and Computed Tomography the Issuer or Public Company Scanning (PET/CT-Scan) in hospitals. This is expected to strengthen the Company's position, particularly in the Prescription Pharmaceuticals Segment. This is the information we can convey. We thank you for your attention and cooperation. Sincerely, PT Kalbe Farma WA . Maria Teresa Fabiola Corporate Secretary PT. KALBE FARMA Tbk. Head Office : Gedung KALBE, Jl. Let. Jend. Suprapto Kav. 4, Jakarta 10510, PO. Box 9105 JAK, Jakarta, Indonesia. Tel. (021) 42873088 -89 Fax. (021) 42673680 Factory : Kawasan Industri Delta Silicon, Jl. M. H. Tharnrin Blok A3 - 1, Lippo Cikarang, Bekasi 17550, P.O. Box 371 Bekasi 17037, Indonesia. Tel. (021)89907333 Fax. (021)8972874 info@kalbe.co,id
Names mentioned 8 people and organisations named in the text · linked when the evidence is strong
unresolved
org
Financial Services Authority
p.1 ×2
unresolved
org
PT Global Onkolab Farma
p.1
unresolved
person
H. Thamrin
p.1
unresolved
org
PT Kalbe Farma WA
p.2
unresolved
person
Maria Teresa Fabiola
· Corporate Secretary
p.2
unresolved
person
H. Tharnrin
p.2
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.